Skip to content
value.today

Pfizer Inc.: peers

Change the peers

Pfizer Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

Pfizer Inc., Bristol-Myers Squibb Company, Amgen Inc., Merck & Co., Inc., Gilead Sciences, Inc., AbbVie Inc., Biogen Inc., Zoetis Inc. side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasurePfizer Inc.base
PFE · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Bristol-Myers Squibb Company
BMY · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Amgen Inc.
AMGN · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Merck & Co., Inc.
MRK · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Gilead Sciences, Inc.
GILD · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
AbbVie Inc.
ABBV · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Biogen Inc.
BIIB · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Zoetis Inc.
ZTS · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Group median
Size
Market cap (Better neither way: ranked highest first)$170.7 BOct 30, 2026 · Market data5th of 8$125.5 BOct 30, 2026 · Market data6th of 8$249.2 BOct 30, 2026 · Market data3rd of 8$359.8 BOct 19, 2026 · Market data2nd of 8$193.5 BOct 26, 2026 · Market data4th of 8$514.0 BOct 30, 2026 · Market data1st of 8$37.5 BOct 23, 2026 · Market data7th of 8$32.9 BOct 26, 2026 · Market data8th of 8$182.1 B8 ranked
Revenue (Better neither way: ranked highest first)$62.6 BFY2025 · SEC2nd of 7$48.2 BFY2025 · SEC4th of 7$36.8 BFY2025 · SEC5th of 7$65.0 BFY2025 · SEC1st of 7——$61.2 BFY2025 · SEC3rd of 7$9.9 BFY2025 · SEC6th of 7$9.5 BFY2025 · SEC7th of 7$48.2 B7 ranked
Net income (Higher is better)$7.8 BFY2025 · SEC2nd of 7$7.1 BFY2025 · SEC4th of 7$7.7 BFY2025 · SEC3rd of 7$18.3 BFY2025 · SEC1st of 7——$4.2 BFY2025 · SEC5th of 7$1.3 BFY2025 · SEC7th of 7$2.7 BFY2025 · SEC6th of 7$7.1 B7 ranked
Employees (Better neither way: ranked highest first)75,000December 31, 2025 · Profile1st of 832,500December 31, 2025 · Profile4th of 825,200As on Dec-2022 · Profile5th of 875,000December 31, 2025 · Profile1st of 817,000As on 2022 · Profile6th of 857,000December 31, 2025 · Profile3rd of 87,500December 31, 2025 · Profile7th of 81,700December 31, 2025 · Profile8th of 828,8508 ranked
Growth
Revenue growth (Higher is better)-1.6%FY2025 · SEC7th of 722nd25th-0.2%FY2025 · SEC6th of 726th28th+9.9%FY2025 · SEC1st of 749th61st+1.3%FY2025 · SEC5th of 729th33rd————+8.6%FY2025 · SEC2nd of 746th57th+2.2%FY2025 · SEC4th of 731st36th+2.3%FY2025 · SEC3rd of 731st36th+2.2%7 ranked
Revenue growth, 3 years a year (Higher is better)-14.8%FY2025 · SEC7th of 710th6th+1.4%FY2025 · SEC5th of 731st38th+11.8%FY2025 · SEC1st of 758th73rd+3.1%FY2025 · SEC3rd of 737th45th————+1.8%FY2025 · SEC4th of 732nd39th-0.9%FY2025 · SEC6th of 725th29th+5.4%FY2025 · SEC2nd of 743rd54th+1.8%7 ranked
Earnings per share growth (Higher is better)-3.5%FY2025 · SEC5th of 632nd33rd————+88.2%FY2025 · SEC1st of 686th88th+8.0%FY2025 · SEC3rd of 649th48th————-1.3%FY2025 · SEC4th of 635th36th-21.4%FY2025 · SEC6th of 621st21st+10.1%FY2025 · SEC2nd of 651st51st+3.4%6 ranked
Margins and returns
Gross margin (Higher is better)74.3%FY2025 · SEC3rd of 773rd86th71.1%FY2025 · SEC5th of 769th83rd67.3%FY2025 · SEC7th of 764th80th74.8%FY2025 · SEC2nd of 774th87th————70.2%FY2025 · SEC6th of 769th83rd75.7%FY2025 · SEC1st of 775th88th71.8%FY2025 · SEC4th of 771st84th71.8%7 ranked
Operating margin (Higher is better)————————24.7%FY2025 · SEC1st of 292nd90th————————24.6%FY2025 · SEC2nd of 292nd90th————————24.7%2 ranked
Net margin (Higher is better)12.4%FY2025 · SEC6th of 782nd79th14.6%FY2025 · SEC4th of 785th83rd21.0%FY2025 · SEC3rd of 791st90th28.1%FY2025 · SEC2nd of 793rd94th————6.9%FY2025 · SEC7th of 773rd67th13.1%FY2025 · SEC5th of 783rd81st28.2%FY2025 · SEC1st of 793rd94th14.6%7 ranked
Free cash flow margin (Higher is better)14.5%FY2025 · SEC7th of 780th80th26.6%FY2025 · SEC2nd of 794th94th22.0%FY2025 · SEC4th of 791st90th19.0%FY2025 · SEC6th of 786th87th————29.1%FY2025 · SEC1st of 796th95th20.7%FY2025 · SEC5th of 789th89th24.1%FY2025 · SEC3rd of 792nd92nd22.0%7 ranked
Return on equity (Higher is better)8.9%FY2025 · SEC5th of 680th61st40.5%FY2025 · SEC3rd of 696th95th106.1%FY2025 · SEC1st of 699th99th36.9%FY2025 · SEC4th of 696th94th————————7.4%FY2025 · SEC6th of 678th57th65.3%FY2025 · SEC2nd of 698th97th38.7%6 ranked
Return on invested capital (Higher is better)————————14.4%FY2025 · SEC2nd of 261st64th————————16.0%FY2025 · SEC1st of 266th69th————————15.2%2 ranked
Valuation
P/E ratio (Better neither way: ranked highest first)42.3×price Oct 30, 2026 · Market data4th of 766th83rd13.6×price Oct 30, 2026 · Market data6th of 719th32nd26.5×price Oct 30, 2026 · Market data5th of 745th66th146.7×price Oct 19, 2026 · Market data1st of 792nd96th————49.7×price Oct 30, 2026 · Market data3rd of 771st87th108.0×price Oct 23, 2026 · Market data2nd of 790th95th13.1×price Oct 26, 2026 · Market data7th of 718th30th42.3×7 ranked
Price to sales (Better neither way: ranked highest first)2.7×price Oct 30, 2026 · Market data7th of 841st56th2.5×price Oct 30, 2026 · Market data8th of 839th54th6.4×price Oct 30, 2026 · Market data2nd of 863rd82nd5.3×price Oct 19, 2026 · Market data4th of 858th79th6.3×price Oct 26, 2026 · Market data3rd of 862nd82nd7.8×price Oct 30, 2026 · Market data1st of 868th86th3.6×price Oct 23, 2026 · Market data5th of 850th68th3.5×price Oct 26, 2026 · Market data6th of 848th66th4.5×8 ranked
Price to book (Better neither way: ranked highest first)2.0×price Oct 30, 2026 · Market data7th of 738th47th6.8×price Oct 30, 2026 · Market data5th of 775th83rd28.8×price Oct 30, 2026 · Market data1st of 795th97th6.8×price Oct 19, 2026 · Market data4th of 776th83rd8.5×price Oct 26, 2026 · Market data3rd of 781st87th————2.1×price Oct 23, 2026 · Market data6th of 739th49th9.6×price Oct 26, 2026 · Market data2nd of 783rd89th6.8×7 ranked
Free cash flow yield (Higher is better)5.3%price Oct 30, 2026 · Market data4th of 888th68th10.2%price Oct 30, 2026 · Market data1st of 894th87th3.3%price Oct 30, 2026 · Market data8th of 879th55th3.4%price Oct 19, 2026 · Market data7th of 880th56th4.9%price Oct 26, 2026 · Market data5th of 887th66th3.5%price Oct 30, 2026 · Market data6th of 880th56th5.5%price Oct 23, 2026 · Market data3rd of 888th69th6.9%price Oct 26, 2026 · Market data2nd of 891st76th5.1%8 ranked
Financial strength
Debt to equity (Lower is better)0.7×FY2025 · SEC2nd of 665th55th2.4×FY2025 · SEC4th of 691st89th6.3×FY2025 · SEC6th of 696th96th0.9×FY2025 · SEC3rd of 673rd64th————————0.3×FY2025 · SEC1st of 642nd33rd2.6×FY2025 · SEC5th of 692nd89th1.7×6 ranked
Net debt to EBITDA (Lower is better)————————3.2×FY2025 · SEConly one with it70th65th————————————————————3.2×—
Interest cover (Higher is better)————————3.3×FY2025 · SEC2nd of 283rd68th————————5.2×FY2025 · SEC1st of 287th75th————————4.3×2 ranked
Piotroski F-score (Higher is better)5 of 9FY2025 · SEC5th of 78 of 9FY2025 · SEC1st of 77 of 9FY2025 · SEC3rd of 74 of 9FY2025 · SEC6th of 7——8 of 9FY2025 · SEC1st of 74 of 9FY2025 · SEC6th of 76 of 9FY2025 · SEC4th of 76.0 of 97 ranked
Scorecard
Scorecard (Higher is better)11 of 21FY2025 · Scorecard5th of 717 of 24FY2025 · Scorecard2nd of 720 of 30FY2025 · Scorecard3rd of 716 of 24FY2025 · Scorecard3rd of 7——13 of 27FY2025 · Scorecard6th of 79 of 19FY2025 · Scorecard7th of 718 of 23FY2025 · Scorecard1st of 767% passed7 ranked
Valuation checks (Higher is better)3 of 6FY2025 · Scorecard2nd of 75 of 6FY2025 · Scorecard1st of 71 of 6FY2025 · Scorecard5th of 70 of 6FY2025 · Scorecard6th of 7——0 of 6FY2025 · Scorecard6th of 72 of 6FY2025 · Scorecard4th of 73 of 6FY2025 · Scorecard2nd of 733% passed7 ranked
Growth checks (Higher is better)0 of 6FY2025 · Scorecard7th of 72 of 6FY2025 · Scorecard4th of 76 of 6FY2025 · Scorecard1st of 75 of 6FY2025 · Scorecard3rd of 7——2 of 6FY2025 · Scorecard4th of 71 of 6FY2025 · Scorecard6th of 76 of 6FY2025 · Scorecard1st of 733% passed7 ranked
Profitability checks (Higher is better)2 of 3FY2025 · Scorecard5th of 72 of 3FY2025 · Scorecard5th of 75 of 6FY2025 · Scorecard3rd of 73 of 3FY2025 · Scorecard1st of 7——4 of 5FY2025 · Scorecard4th of 72 of 3FY2025 · Scorecard5th of 73 of 3FY2025 · Scorecard1st of 780% passed7 ranked
Financial health checks (Higher is better)3 of 3FY2025 · Scorecard1st of 72 of 3FY2025 · Scorecard5th of 73 of 6FY2025 · Scorecard7th of 73 of 3FY2025 · Scorecard1st of 7——3 of 4FY2025 · Scorecard4th of 73 of 3FY2025 · Scorecard1st of 72 of 3FY2025 · Scorecard5th of 775% passed7 ranked
Shareholder returns checks (Higher is better)3 of 3FY2025 · Scorecard1st of 76 of 6FY2025 · Scorecard1st of 75 of 6FY2025 · Scorecard4th of 75 of 6FY2025 · Scorecard4th of 7——4 of 6FY2025 · Scorecard7th of 71 of 1FY2025 · Scorecard1st of 74 of 5FY2025 · Scorecard6th of 783% passed7 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)66.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 880.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 881.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 878.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 886.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 874.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 894.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 893.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 880.7%8 ranked
Institutions holding (Better neither way: ranked highest first)2,9082026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 82,5622026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 83,2632026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 83,9602026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 82,3492026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 84,2722026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 81,0592026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 81,3572026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 82,7358 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)+1.6 pp2026-Q2 against 2026-Q1 · 13F7th of 8+3.2 pp2026-Q2 against 2026-Q1 · 13F4th of 8+3.4 pp2026-Q2 against 2026-Q1 · 13F3rd of 8+2.3 pp2026-Q2 against 2026-Q1 · 13F5th of 8+4.6 pp2026-Q2 against 2026-Q1 · 13F2nd of 8+2.1 pp2026-Q2 against 2026-Q1 · 13F6th of 8+5.3 pp2026-Q2 against 2026-Q1 · 13F1st of 8-1.2 pp2026-Q2 against 2026-Q1 · 13F8th of 8+2.7 pp8 ranked
Dividends
Dividend yield (Higher is better)————4.0%FY2025 · SEC1st of 491st79th2.1%FY2025 · SEC4th of 471st49th2.3%FY2025 · SEC2nd of 479th54th————2.3%FY2025 · SEC2nd of 479th54th————————2.3%4 ranked
Shareholder yield (Higher is better)————4.0%FY2025 · SEC2nd of 570th59th2.1%FY2025 · SEC5th of 548th35th3.7%FY2025 · SEC3rd of 565th56th————2.5%FY2025 · SEC4th of 552nd40th————9.8%FY2025 · SEC1st of 590th88th3.7%5 ranked
Dividend payout (Better neither way: ranked highest first)————71.5%FY2025 · SEC2nd of 489th76th66.5%FY2025 · SEC3rd of 483rd73rd44.8%FY2025 · SEC4th of 472nd58th————275.8%FY2025 · SEC1st of 498th97th————————69.0%4 ranked
Dividend per share (Better neither way: ranked highest first)$1.72FY2025 · SEC6th of 6$2.49FY2025 · SEC4th of 6$9.66FY2025 · SEC1st of 6$3.28FY2025 · SEC3rd of 6——$6.65FY2025 · SEC2nd of 6——$2.03FY2025 · SEC5th of 6$2.886 ranked
Years of dividend raises (Higher is better)15to 2025 · SEC2nd of 716to 2025 · SEC1st of 712to 2025 · SEC4th of 715to 2025 · SEC2nd of 710to 2025 · SEC6th of 73to 2025 · SEC7th of 7——12to 2025 · SEC4th of 7127 ranked

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Pfizer Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Bristol-Myers Squibb Company: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Amgen Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Merck & Co., Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Gilead Sciences, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; AbbVie Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Biogen Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Zoetis Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
Pfizer Inc.———
Bristol-Myers Squibb Company———
Amgen Inc.24.7%FY2025
92nd percentile in Healthcaremedian -7.8%, 678 companies
90th percentile in USAmedian 3.4%, 2,607 companies
Merck & Co., Inc.———
Gilead Sciences, Inc.———
AbbVie Inc.24.6%FY2025
92nd percentile in Healthcaremedian -7.8%, 678 companies
90th percentile in USAmedian 3.4%, 2,607 companies
Biogen Inc.———
Zoetis Inc.———

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$25.3 B$50.6 B$75.9 B$101.2 B200820102012201420162018202020222024Pfizer Inc. $62.6 BBristol-Myers Squibb Company $48.2 BAmgen Inc. $36.8 BMerck & Co., Inc. $65.0 BGilead Sciences, Inc. $29.4 BAbbVie Inc. $61.2 BBiogen Inc. $9.9 BZoetis Inc. $9.5 B

Rank in the group

1st2nd3rd4th5th6th7th8th201120122013201420152016201720182019202020212022202320242025Pfizer Inc.: 1st of 8 in 2011Pfizer Inc.: 1st of 8 in 2012Pfizer Inc.: 1st of 8 in 2013Pfizer Inc.: 1st of 8 in 2014Pfizer Inc.: 1st of 8 in 2015Pfizer Inc.: 1st of 8 in 2016Pfizer Inc.: 1st of 8 in 2017Pfizer Inc.: 2nd of 8 in 2018Pfizer Inc.: 1st of 8 in 2019Pfizer Inc.: 3rd of 8 in 2020Pfizer Inc.: 1st of 8 in 2021Pfizer Inc.: 1st of 8 in 2022Pfizer Inc.: 2nd of 8 in 2023Pfizer Inc.: 2nd of 8 in 2024Pfizer Inc.: 2nd of 8 in 2025Pfizer Inc.Bristol-Myers Squibb Company: 3rd of 8 in 2011Bristol-Myers Squibb Company: 4th of 8 in 2012Bristol-Myers Squibb Company: 5th of 8 in 2013Bristol-Myers Squibb Company: 6th of 8 in 2014Bristol-Myers Squibb Company: 6th of 8 in 2015Bristol-Myers Squibb Company: 6th of 8 in 2016Bristol-Myers Squibb Company: 6th of 8 in 2017Bristol-Myers Squibb Company: 5th of 8 in 2018Bristol-Myers Squibb Company: 4th of 8 in 2019Bristol-Myers Squibb Company: 2nd of 8 in 2020Bristol-Myers Squibb Company: 4th of 8 in 2021Bristol-Myers Squibb Company: 4th of 8 in 2022Bristol-Myers Squibb Company: 4th of 8 in 2023Bristol-Myers Squibb Company: 4th of 8 in 2024Bristol-Myers Squibb Company: 4th of 8 in 2025Bristol-Myers Squibb CompaAmgen Inc.: 5th of 8 in 2011Amgen Inc.: 5th of 8 in 2012Amgen Inc.: 4th of 8 in 2013Amgen Inc.: 4th of 8 in 2014Amgen Inc.: 5th of 8 in 2015Amgen Inc.: 5th of 8 in 2016Amgen Inc.: 5th of 8 in 2017Amgen Inc.: 4th of 8 in 2018Amgen Inc.: 5th of 8 in 2019Amgen Inc.: 5th of 8 in 2020Amgen Inc.: 6th of 8 in 2021Amgen Inc.: 6th of 8 in 2022Amgen Inc.: 5th of 8 in 2023Amgen Inc.: 5th of 8 in 2024Amgen Inc.: 5th of 8 in 2025Amgen Inc.Merck & Co., Inc.: 2nd of 8 in 2011Merck & Co., Inc.: 2nd of 8 in 2012Merck & Co., Inc.: 2nd of 8 in 2013Merck & Co., Inc.: 2nd of 8 in 2014Merck & Co., Inc.: 2nd of 8 in 2015Merck & Co., Inc.: 2nd of 8 in 2016Merck & Co., Inc.: 2nd of 8 in 2017Merck & Co., Inc.: 1st of 8 in 2018Merck & Co., Inc.: 2nd of 8 in 2019Merck & Co., Inc.: 4th of 8 in 2020Merck & Co., Inc.: 3rd of 8 in 2021Merck & Co., Inc.: 2nd of 8 in 2022Merck & Co., Inc.: 1st of 8 in 2023Merck & Co., Inc.: 1st of 8 in 2024Merck & Co., Inc.: 1st of 8 in 2025Merck & Co., Inc.Gilead Sciences, Inc.: 6th of 8 in 2011Gilead Sciences, Inc.: 6th of 8 in 2012Gilead Sciences, Inc.: 6th of 8 in 2013Gilead Sciences, Inc.: 3rd of 8 in 2014Gilead Sciences, Inc.: 3rd of 8 in 2015Gilead Sciences, Inc.: 3rd of 8 in 2016Gilead Sciences, Inc.: 4th of 8 in 2017Gilead Sciences, Inc.: 6th of 8 in 2018Gilead Sciences, Inc.: 6th of 8 in 2019Gilead Sciences, Inc.: 6th of 8 in 2020Gilead Sciences, Inc.: 5th of 8 in 2021Gilead Sciences, Inc.: 5th of 8 in 2022Gilead Sciences, Inc.: 6th of 8 in 2023Gilead Sciences, Inc.: 6th of 8 in 2024Gilead Sciences, Inc.: 6th of 8 in 2025Gilead Sciences, Inc.AbbVie Inc.: 4th of 8 in 2011AbbVie Inc.: 3rd of 8 in 2012AbbVie Inc.: 3rd of 8 in 2013AbbVie Inc.: 5th of 8 in 2014AbbVie Inc.: 4th of 8 in 2015AbbVie Inc.: 4th of 8 in 2016AbbVie Inc.: 3rd of 8 in 2017AbbVie Inc.: 3rd of 8 in 2018AbbVie Inc.: 3rd of 8 in 2019AbbVie Inc.: 1st of 8 in 2020AbbVie Inc.: 2nd of 8 in 2021AbbVie Inc.: 3rd of 8 in 2022AbbVie Inc.: 3rd of 8 in 2023AbbVie Inc.: 3rd of 8 in 2024AbbVie Inc.: 3rd of 8 in 2025AbbVie Inc.Biogen Inc.: 7th of 8 in 2011Biogen Inc.: 7th of 8 in 2012Biogen Inc.: 7th of 8 in 2013Biogen Inc.: 7th of 8 in 2014Biogen Inc.: 7th of 8 in 2015Biogen Inc.: 7th of 8 in 2016Biogen Inc.: 7th of 8 in 2017Biogen Inc.: 7th of 8 in 2018Biogen Inc.: 7th of 8 in 2019Biogen Inc.: 7th of 8 in 2020Biogen Inc.: 7th of 8 in 2021Biogen Inc.: 7th of 8 in 2022Biogen Inc.: 7th of 8 in 2023Biogen Inc.: 7th of 8 in 2024Biogen Inc.: 7th of 8 in 2025Biogen Inc.Zoetis Inc.: 8th of 8 in 2011Zoetis Inc.: 8th of 8 in 2012Zoetis Inc.: 8th of 8 in 2013Zoetis Inc.: 8th of 8 in 2014Zoetis Inc.: 8th of 8 in 2015Zoetis Inc.: 8th of 8 in 2016Zoetis Inc.: 8th of 8 in 2017Zoetis Inc.: 8th of 8 in 2018Zoetis Inc.: 8th of 8 in 2019Zoetis Inc.: 8th of 8 in 2020Zoetis Inc.: 8th of 8 in 2021Zoetis Inc.: 8th of 8 in 2022Zoetis Inc.: 8th of 8 in 2023Zoetis Inc.: 8th of 8 in 2024Zoetis Inc.: 8th of 8 in 2025Zoetis Inc.
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearPfizer Inc.Bristol-Myers Squibb CompanyAmgen Inc.Merck & Co., Inc.Gilead Sciences, Inc.AbbVie Inc.Biogen Inc.Zoetis Inc.
2025$62.6 BSEC2nd$48.2 BSEC4th$36.8 BSEC5th$65.0 BSEC1st$29.4 BSEC6th$61.2 BSEC3rd$9.9 BSEC7th$9.5 BSEC8th
2024$63.6 BSEC2nd$48.3 BSEC4th$33.4 BSEC5th$64.2 BSEC1st$28.8 BSEC6th$56.3 BSEC3rd$9.7 BSEC7th$9.3 BSEC8th
2023$59.6 BSEC2nd$45.0 BSEC4th$28.2 BSEC5th$60.1 BSEC1st$27.1 BSEC6th$54.3 BSEC3rd$9.8 BSEC7th$8.5 BSEC8th
2022$101.2 BSEC1st$46.2 BSEC4th$26.3 BSEC6th$59.3 BSEC2nd$27.3 BSEC5th$58.1 BSEC3rd$10.2 BSEC7th$8.1 BSEC8th
2021$81.3 BSEC1st$46.4 BSEC4th$26.0 BSEC6th$48.7 BSEC3rd$27.3 BSEC5th$56.2 BSEC2nd$11.0 BSEC7th$7.8 BSEC8th
2020$41.7 BSEC3rd$42.5 BSEC2nd$25.4 BSEC5th$41.5 BSEC4th$24.7 BSEC6th$45.8 BSEC1st$13.4 BSEC7th$6.7 BSEC8th
2019$40.9 BSEC1st$26.1 BSEC4th$23.4 BSEC5th$39.1 BSEC2nd$22.4 BSEC6th$33.3 BSEC3rd$14.4 BSEC7th$6.3 BSEC8th
2018$40.8 BSEC2nd$22.6 BSEC5th$23.7 BSEC4th$42.3 BSEC1st$22.1 BSEC6th$32.8 BSEC3rd$13.5 BSEC7th$5.8 BSEC8th
2017$52.5 BSEC1st$20.8 BSEC6th$22.8 BSEC5th$40.1 BSEC2nd$26.1 BSEC4th$28.2 BSEC3rd$12.3 BSEC7th$5.3 BSEC8th
2016$52.8 BSEC1st$19.4 BSEC6th$23.0 BSEC5th$39.8 BSEC2nd$30.4 BSEC3rd$25.6 BSEC4th$11.4 BSEC7th$4.9 BSEC8th
2015$48.9 BSEC1st$16.6 BSEC6th$21.7 BSEC5th$39.5 BSEC2nd$32.6 BSEC3rd$22.9 BSEC4th$10.8 BSEC7th$4.8 BSEC8th
2014$49.6 BSEC1st$15.9 BSEC6th$20.1 BSEC4th$42.2 BSEC2nd$24.9 BSEC3rd$20.0 BSEC5th$9.7 BSEC7th$4.8 BSEC8th

Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of Pfizer Inc.#

Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • Bristol-Myers Squibb CompanyBMY · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $125.5 B market cap against $170.7 B · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $125.5 B (Oct 30, 2026) · revenue $48.2 B (year to December 2025)
    98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)
    In the group
  • Amgen Inc.AMGN · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $249.2 B market cap against $170.7 B · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $249.2 B (Oct 30, 2026) · revenue $36.8 B (year to December 2025)
    98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)
    In the group
  • Merck & Co., Inc.MRK · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $359.8 B market cap against $170.7 B · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $359.8 B (Oct 19, 2026) · revenue $65.0 B (year to December 2025)
    95 of 100 (industry or sector 50 + size 25 + country 15 + figures on file 5)
    In the group
  • Gilead Sciences, Inc.GILD · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $193.5 B market cap against $170.7 B · Same country: USA
    Market cap $193.5 B (Oct 26, 2026) · revenue $29.4 B (year to December 2025)
    94 of 100 (industry or sector 50 + size 29 + country 15)
    In the group
  • AbbVie Inc.ABBV · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $514.0 B market cap against $170.7 B · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $514.0 B (Oct 30, 2026) · revenue $61.2 B (year to December 2025)
    93 of 100 (industry or sector 50 + size 23 + country 15 + figures on file 5)
    In the group
  • Biogen Inc.BIIB · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $37.5 B market cap against $170.7 B · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $37.5 B (Oct 23, 2026) · revenue $9.9 B (year to December 2025)
    90 of 100 (industry or sector 50 + size 20 + country 15 + figures on file 5)
    In the group
  • Zoetis Inc.ZTS · 🇺🇸 USA
    Same industry: Pharmaceutical · 5.2× smaller by market cap · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $32.9 B (Oct 26, 2026) · revenue $9.5 B (year to December 2025)
    89 of 100 (industry or sector 50 + size 19 + country 15 + figures on file 5)
    In the group
  • Eli Lilly and CompanyLLY · 🇺🇸 USA
    Same industry: Pharmaceutical · 7.0× larger by market cap · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $1.20 T (Oct 26, 2026) · revenue $65.2 B (year to December 2025)
    87 of 100 (industry or sector 50 + size 17 + country 15 + figures on file 5)
    + Add
  • Viatris Inc.VTRS · 🇺🇸 USA
    Same industry: Pharmaceutical · 7.8× smaller by market cap · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $22.0 B (Oct 30, 2026) · revenue $14.3 B (year to December 2025)
    87 of 100 (industry or sector 50 + size 17 + country 15 + figures on file 5)
    + Add
  • Johnson & JohnsonJNJ · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $652.5 B market cap against $170.7 B · Same country: USA
    Market cap $652.5 B (Oct 29, 2026) · revenue $94.2 B (year to December 2025)
    86 of 100 (industry or sector 50 + size 21 + country 15)
    + Add
  • AstraZeneca PLCAZN · 🇬🇧 UK
    Same industry: Pharmaceutical · Similar size: $242.6 B market cap against $170.7 B · Ratios of the last two fiscal years on file
    Market cap $242.6 B (Aug 1, 2026) · revenue $58.7 B (year to December 2025)
    83 of 100 (industry or sector 50 + size 28 + figures on file 5)
    + Add
  • Elanco Animal Health IncorporatedELAN · 🇺🇸 USA
    Same industry: Pharmaceutical · 15× smaller by market cap · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $11.3 B (Oct 28, 2026) · revenue $4.7 B (year to December 2025)
    82 of 100 (industry or sector 50 + size 12 + country 15 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.